Biosimilars Market: How Is the Insulin Biosimilar Segment Creating...

2026-06-05 09:59:13 -

Insulin biosimilar commercial access revolution — the commercial launch of insulin glargine biosimilars Semglee (Mylan/Biocon), Basaglar (Lilly/Boehringer), and Rezvoglar (Lilly) creating the first commercial competitive alternatives to Sanofi's Lantus — the world's historically best-selling insulin commercial product — with commercial pricing discounts ranging from fifteen to...

0 ความคิดเห็น 0 แชร์ 54 ยอดวิว 0 รีวิว